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Abstract 
 
Objectives 
Well-being perception is seldom explored in schizophrenia patients. Recurrent limitations, such as the 
questionable applicability of gold standard defintions of health and well-being, and fewer tools available 
to assess well-being, are pronounced in this subpopulation.  This cross-sectional study sought to explore 
potential clinical factors that may predict subjective well-being scores in chronic schizophrenia patients 
(N=142) receiving clozapine treatment, 
Methods 
The Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS) was used to measure well-being. 
We correlated SWEMWBS scores and 27 clinically recognised factors, spanning socio-demographics, 
symptom severity scores, physical health diagnosis, clozapine side effects, habits and prescribed 
medication. Factors with a p<0.2 correlation were included as a predictors in a linear regression model. 
Results 
Ten factors were included in the linear regression model, however only positive symptom severity was a 
significant predictor of SWEMWBS score (p<0.003). 
Conclusions 
The results suggest that the SWEMWBS is an efficient tool for measuring wellbeing in patients with 
chronic schizophrenia. We suggest that greater levels of clinical attention given to positive symptoms 
compared with other symptoms and aspects of well-being, during biomedical treatment for chronic 
schizophrenia, may partially explain the finding that only positive symptoms significantly predicted 
patient perceptions of low well-being.  
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Highlights 
 Lower levels of well-being in schizophrenia need to be clinically accounted for 
 Positive symptoms in chronic schizophrenia influence eudemonic well-being  
 Both quantitative and qualitative research may improve clinical comprehension  
 
 
 
 
1. Introduction  
 
Well-being and health perception is seldom measured in schizophrenia patients, and it is conceivable that 
subjective well-being and health perception amongst schizophrenia patients presents a different context 
from that of general population models. Concepts of health, mental health and quality of life are typically 
situated within the World Health Organisation (WHO) definition of health as ‘complete physical, mental 
and social well-being' [1], and mental health as ‘a state of well-being in which the individual realizes his 
or her own abilities’ [2]. Characteristics of schizophrenia, such as reality distortion, restricted emotional 
life, impaired cognition and lack of personal insight [3], along with antipsychotic side effects such as 
weight gain, sedation, hyper-salivation, or parkinsonism [4, 5], may impinge on well-being conceptions 
such that gold standard definitions and clinical perceptions of wellbeing are incongruent. By investigating 
how patients’ perceptions pertain to gold standard well-being definitions, we may better understand 
patient engagement in health care [6], and better assist patients to achieve full recovery.  
 
It is suggested that ‘health related quality of life’ is significantly lower in persons with schizophrenia than 
in general population comparisons [7]. Previous research has indicated that both physical and mental 
aspects of health, measured separately, correlate with subjective quality of life amongst people with 
serious mental illness [8, 9]. Eudemonic, rather than hedonic, aspects of well-being have been positively 
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linked to biological and psychological resilience to stressors and negative health outcomes [10]. Further, 
lived experience and social situation contribute to subjective perceptions of health and well-being in 
schizophrenia [8, 11]. The influence of clinical perceptions and treatment focus, such as symptom 
alleviation, as part of an individual’s experience and context, should therefore be critical to understanding 
subjective well-being in the course of schizophrenia treatment.  
Clinical ideals of well-being tend to concern symptomatology, while instruments to measure subjective 
well-being concern either symptom severity or general life satisfaction, with mixed evidence of 
concordance with patient perceptions. The extent to which a patients’ perceptions of well-being is 
consistent with clinical perceptions of well-being is unclear [12]. Recent studies suggest that perceptions 
of high quality of life cannot be predicted by levels of cognitive function amongst people with 
schizophrenia [8, 13]. Different studies have attributed patient well-being to different symptom domains 
in schizophrenia, including severity of negative symptoms [14, 15], positive symptoms [11] or depressive 
symptoms [15-17]. However, there is limited replication of these studies and also a lack of consistency in 
measurement tools and treatment variables used.  
When subjective instruments are framed around general life satisfaction rather than symptom severity, 
both positive and depressive symptoms are implicated. Positive symptoms have been found to be 
predictive of lower subjective life satisfaction if queried on its’ own terms using more general sub-scales, 
whereas quality of life based on symptom deficits is predominantly linked with negative symptom 
alleviation [11]. Yet if subjectively rated life satisfaction is framed as a singular query and compared with 
a wide range of clinical variables in a large cohort of chronic schizophrenia patients, depressive 
symptoms have been found to be the most, albeit moderate, predictive clinical factor [17]. Moreover, the 
expanse of items on subjective wellbeing scales, the range of clinical variables including treatment type 
tested, and consideration for illness chronicity may yield different study outcomes. 
To take a particular treatment case study, the clinical determinants of well-being in clozapine treatment 
for schizophrenia may have implications for the treatment of schizophrenia more generally. Clozapine 
prevails as the gold standard treatment for schizophrenia because of its efficacy in alleviating positive 
symptoms and, to some extent, negative symptoms [18]. Compared with other second-generation 
antipsychotic drugs, clozapine treatment has been associated with higher levels of general wellbeing in 
schizophrenia [19], despite potentially debilitating side effects [20].  However, it is not known whether 
positive symptom alleviation in the context of other clinical concerns pertaining to clozapine treatment 
impact eudemonic aspects of wellbeing, otherwise linked to improved general health [10]. It is pertinent 
to understand the relevance of clinical assessments in terms of what constitutes patient well-being under 
schizophrenia treatment regimes like clozapine that may compromise other areas of health and lifestyle.  
In order to disentangle what particular factors may predict patients’ sense of well-being in clozapine 
treatment for schizophrenia, it might be useful to rate ‘mental’ well-being on its own terms to then be 
compared with other variables such as treatment, social situation and symptomology compared to other 
instruments validated to measure holistic functioning amongst clozapine-treated schizophrenia patients 
[19]. The Warwick-Edinburgh Mental Well-being Scale was designed to measure affirmative aspects of 
mental well-being [21]. The Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS) enlists 7 
eudemonic aspects of well-being and is more efficient in terms of patients’ time and willingness to 
respond [22, 23]. While the SWEMWBS is validated for general population use [22, 23] and easy to use 
for both patient and clinicians, it has not been used in schizophrenia and this study might contribute to its 
applicability to this population.  
This study is the first to investigate how eudemonic aspects of well-being compare with clinical 
perceptions of well-being guided by symptom severity in clozapine patients in particular. We investigated 
how patient’s perception of well-being is influenced by a range of clinical factors in a relatively large 
cohort that we characterized as stable clozapine chronic schizophrenia patients. We hypothesized that 
symptom severity, physical health complications, antipsychotic side effects and demographic factors are 
all associated with well-being perception in stable chronic schizophrenia patients treated with clozapine.  
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2. Material and Methods 
 
2.1 Design and Study Sample 
Clinical assessments and subjective well-being assessments of clozapine treated patients were compiled 
from an electronic clinical database at the Cambridgeshire and Peterborough NHS Foundation Trust 
Clozapine Clinic, where all patients receive mandatory monthly blood monitoring (described below) and 
annual review by a consultant psychiatrist. Assessments were collected at the same point in time for each 
participant, between October 2012 and May 2015.  
2.2 Electronic Records 
The Clinical and Research Database for Persistent Schizophrenia is an ethically approved electronic 
database (13/EE/0121) containing two sets of data for the Clozapine Clinic service users: clinical data 
from consultations and research data from service users who are/have participating/participated in 
research studies. All data was de-identified, maintaining anonymity. Data from October 2012 to June 
2015 were included in the analysis.  
 
2.3 Inclusion/Exclusion criteria 
The study only included stable chronic schizophrenia patients. Non-schizophrenia patients [24] and those 
with less than four years of continuous treatment with clozapine or who were clinically unstable 
(measured as changes of more than 10 points at the GAF scale in two years) were excluded from the final 
analysis. 
 
2.4 Measures of Assessment 
Assessments included were: review and confirmation of all prescribed medication (latest clozapine 
plasma levels results), current smoking habit (average number of cigarettes per day) and alcohol use 
(average number of alcohol units per week), assessment of physical exercise using the General 
Practitioner Physical Activity Questionnaire (“General Practice Physical Activity Questionnaire 
(GPPAQ) – Publication – GOV.UK” 2015) and clozapine common side effects specific assessment 
(hours of sleep per day, constipation, hypersalivation, obsessive symptoms, Type 2 Diabetes Mellitus -
T2DM-, hypertension, hyperlipidaemia and obesity) and different symptoms rating scales for symptom 
severity assessment, such as Global Assessment of Functioning (GAF) [25, 26], the Clinical Global 
Impression-schizophrenia (CGI-SCH) [27] and the Short Warwick-Edinburgh Mental Well-being Scale 
(SWEMWBS) [22]. 
The GAF is a clinician rated scale of functioning (0-100) and has been validated for assessing symptom 
severity and social functioning among people with chronic schizophrenia rather than acute psychosis [28]. 
It is therefore an appropriate assessment tool for clozapine patients. The CGI-SCH [22] is a validated 
version of the CGI [29] specific for schizophrenia, rating symptom severity on a scale of 1-7 (‘normal, 
not at all ill’ (1); ‘borderline mentally ill’ (2); ‘mildly ill’ (3); ‘moderately ill’ (4); ‘markedly ill’ (5); 
‘severely ill’ (6); ‘among the most extremely ill patients’ (7). Mildly ill (3) is generally considered to be 
the threshold for clinically relevant psychopathology. In regards to positive symptom alleviation, the 
CGI-SCH includes four domains (positive, negative, depressive and cognitive symptoms) and an overall 
score (which mimics the CGI) [27, 30].  
Our study used the SWEMWBS [22], which asks participants to nominate how often (‘none of the time’; 
‘rarely’; ‘some of the time’; ‘often’; ‘all of the time’) the following statements have applied to them in the 
last two weeks: 1) ‘I’ve been feeling optimistic about the future’; 2) ‘I’ve been feeling useful’; 3) ‘I’ve 
been feeling relaxed’; 4) ‘I’ve been dealing with problems well’ 5) ‘I’ve been thinking clearly’; 6) ‘I’ve 
been feeling close to other people’; 7) ‘I’ve been able to make up my mind about things’. An internal 
construct validity study [21] was used to correct final scores, which ranged from 7 to 35; a high score 
reflecting a high level of well-being perception.  
Pharmacological treatment was accounted for in terms of whether participants were taking only clozapine 
(‘monotherapy’), or clozapine combined with other psychoactive pharmaceuticals (See table 1). 
2.5 Statistical analysis  
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Clinical, self-rated and demographic variables were measured using descriptive statistics. The relationship 
between variables was determined using Pearson’s correlation. Chi-square was used for categorical 
comparisons. 
 
The following research question was interrogated:  
Which clinically recognized factors correlate with patient well-being perception? We used a 2 stages 
approach [31] to answer this question. First, among the 27 factors aforementioned (see table 1), we 
determined those factors that were associated with well-being, aiming to be over inclusive and setting a 
threshold of p<0.2. A multiple regression model was built in a stepwise procedure retaining candidate 
variables with the previously established threshold and using the SWEMWBS mean score as dependent 
variable. We selected the option backward elimination (BE), which involves starting with all candidate 
variables, testing the deletion of each variable using a chosen model comparison criterion, deleting the 
variable that improves the model the most by being deleted, and repeating this process until no further 
improvement is possible [31].  
 
For all analyses, the level of statistical significance was defined as p<0.05 (two-tailed). Statistical analysis 
was carried out using the SPSS programme (version 19.0). 
 
 
3. Results  
 
Of the 175 subjects included in the database, 15 subjects were excluded from the initial sample due to 
differential diagnosis (i.e. schizoaffective disorder, off label use for borderline personality disorder) and 
27 due to not having clinical and clozapine treatment stability, as defined by the inclusion criteria. The 
final sample included 145 subjects. Demographic, baseline clinical and treatment characteristics of the 
subjects are presented in Table 2.  
 
The mean well-being score and GAF was 21.64 (SD=3.89; See Figure 1) and 68.82 (SD=15.09), 
respectively.  
The ten main factors associated with well-being with a p<0.2, which we included in the regression model, 
are shown in Appendix A. Backward multiple regression revealed that positive symptoms severity (CGI-
Positive) significantly predicted SWEMWBS score (p<0.001). The SWEMWBS score was not 
significantly associated with any other symptom severity scores or clinical factors such as type of 
treatment or additional treatment for side effects of clozapine (p>0.05). The overall model is statistically 
significant  (F (3, 122)= 6.02, p<.001) and accounts for 14.5% of the variance (R= 0.381, R
2
=0.145) (see 
Table 3 for the full model).  
 
 
4. Discussion  
 
This study supports that the SWEMWBS is an efficient tool for assessing subjective well-being in 
clozapine treatment for schizophrenia. We found that only positive symptoms were a predictor of low 
subjective well-being amongst this population of stable patients. In light of previous quantitative and 
qualitative research, this finding should be contextualized in terms of how clinical attention to various 
aspects of symptomology and treatment might shape patients’ own perceptions of health and well-being.  
 
Firstly, the mean SWEMWBS  (21.64) for our chronic schizophrenia patient sample was lower than that 
of a general population sample (23.61; obtained through personal communication with the authors of the 
SWEMWBS and the SWEMBWS online resource based the 2011 Health Survey for England [32, 33]). 
This finding is consistent with previous research [7], emphasizing a need to improve eudemonic well-
being in treatment for chronic schizophrenia. The normal distribution suggests that the SWEMWBS is a 
useful tool for measuring subjective well-being in patients with chronic schizophrenia. 
The finding that only one type of symptom alleviation and no lifestyle factors correlated with subjective 
well-being in this study deserves careful consideration. Contrary to our hypothesis, we found that only 
positive symptoms may be a predisposing factor for low subjective well-being. No associations were 
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found between other variables such as negative and depressive symptoms, the type of treatment, the 
presence of side effects due to clozapine, alcohol and tobacco consumption or other demographical 
variables. The relationship between positive symptoms and subjective general well-being supports the 
findings of another study [11]. However, our study provides the first example of a statistical relationship 
between positive symptoms and, specifically, eudemonic aspects of well-being. Other studies utilizing 
more extensive tools in terms of time and range of well-being factors have found depressive symptoms to 
be predictive of subjective well-being [16, 34, 35], albeit these studies included no stable patients and 
smaller sample sizes.  
As our study separated out other variables that might predict eudemonic well-being, our finding that only 
positive symptoms correlated with SWEMWBS score, supports clinical assumptions that psychotic 
symptoms impact an individuals’ sense of capability. This finding also supports the positive benefit-to-
risk ratio pertaining to clozapine treatment, whereby additional health risks are clinically understood to be 
secondary to the potential for positive symptom alleviation [18]. This is particularly important as our 
sample included stable patients, in which psychosis severity seems to be the main driver of distress.  
Interestingly, this finding supports an American ethnographic study that found patient interpretations of 
‘recovery’ to mostly concern psychotic symptom alleviation in spite of extensive reporting of medication-
associated side-effects [36]. As qualitative research findings assert, whether or not patients themselves de-
emphasise the illness or medication effects in their conceptions of well-being is critical to understanding 
the impact of clinical judgments on a person’s subjectivity [36, 37]. As the SWEMWBS does not make 
mention of symptoms but rather perceptions of self efficacy and potential, our study suggests that the 
presence of psychotic symptoms may indeed contribute to what anthropologists term ‘social defeat’ in 
schizophrenia, in a Western biomedical context [38]. Regardless of whether the negative experience of 
psychotic symptoms may be culturally confined [39, 40], the biomedical priority of alleviating psychosis 
remains important for improving an individuals’ sense of capability given the Western social context. 
However, it should also be noted that this finding might reflect the emphasis on positive symptoms 
inherent to antipsychotic treatment regimens. Moreover, the bivariate correlation between positive 
symptom severity and well-being perception was not strong, suggesting that there should be more factors 
associated with well-being that deserve further investigation, possibly incorporating qualitative research 
into this specific population.  
Arguably, the influence of negative symptoms, depressive symptoms and lifestyle behaviours on an 
individuals’ sense of well-being, health and quality of life may gain more traction as important aspects if 
given more clinical attention, especially in regards to patients who present with lack of insight into their 
primary health condition.  As our study did not include measures of level of insight, our finding that 
positive symptoms predict low levels of well-being may be confounded by the possibility that concordant 
clozapine patients, subscribing to an end-of-the-line regular monitoring regime, are less likely to lack 
insight into a need for antipsychotic medication. Alternatively, the persistence of negative and depressive 
symptoms along with lifestyle behaviours, in spite of subjective well-being levels, may point to greater 
issues of patient disconnection from - and subsequently poor insight into - vulnerabilities associated with 
physical, mental, and social well-being. Given that depressive symptoms influence subjective well-being 
amongst clozapine patients if the measurement is framed around a variety of well-being aspects [16], 
further research is needed to investigate the interplay between clinical symptomology and patient 
perceptions.  
The interpretation of the results should be considered in light of some limitations. Firstly, our study is 
cross-sectional and it is not possible to establish a true cause and effect relationship between psychotic 
symptoms and subjective well-being [41]. A longitudinal study would establish consistency of results 
over time. Secondly, because this study is naturalistic and without randomization, clinician bias might 
have been present in the symptomatology rating scores, although symptom severity scores were done 
immediately before patients completed the well-being scale. Thirdly, socioeconomic variables could be 
controlled for in future studies. Finally, this study did not employ a scale to assess other aspects of quality 
of life, to compare against eudemonic framing of well-being, nor were we able to include a measurement 
for patient insight. Future studies might also include observed-rated scales in addition to self-reporting in 
order to capture the correlates of subjective well-being, quality of life and functional outcome. 
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Additionally, qualitative data may compliment efforts to understand how other aspects of symptomology 
and treatment, not found to be significant in so far as predicting SWEMWBS score, may impact quality of 
life in chronic schizophrenia. 
In conclusion, the results of our study suggest that positive symptoms are predictive of low well-being 
perception in chronic schizophrenia patients receiving clozapine treatment. Given the current situation of 
questionable health-related quality of life and well-being among people with chronic schizophrenia on 
long-term treatment regimes, it is critical to utilize efficient subjective measures of well-being such as the 
SWEMWBS, and to attend to how clinical perceptions of patients’ general functioning in schizophrenia 
reflect patients’ views. Moreover, the extent to which perceived functioning and well-being are associated 
with longer-term outcomes such as relapse, co-morbidities, and treatment concordance requires ongoing 
quantitative and qualitative research efforts to identify which domains and measures of health-related 
quality of life are most germane to treating schizophrenia. 
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Table 1. Measures of assessment and variables included in the study: 
Demographical variables 
Gender (male / female) 
Age (years) 
Age of FEP (years) 
Smoking habit (average number of cigarettes per day) 
Alcohol use (average number of alcohol units per week) 
Prescribed medication Latest clozapine plasma levels results 
Physical activity General Practitioner Physical Activity Questionnaire (GPPAQ) 
Clinical Assessment 
CGI- Positive 
CGI- Negative 
CGI- Depressive 
CGI- Cognitive 
CGI- Overall 
GAF 
Corrected Short Warwick-Edinburgh Mental Well-being Scale (cSWEMWBS) 
Clozapine main side effects 
Hypersalivation 
Hours of sleep per day 
Constipation 
Obsessive symptoms 
Hypertension 
Overweight 
Hyper-lipidaemia 
Type 2 diabetes mellitus 
Pharmacological treatment 
Monotherapy with clozapine 
Clozapine combined  
with other drugs 
Clozapine and Other antipsychotics 
 
Clozapine and Antidepressants 
Clozapine and Drugs for side effect symptoms 
(beta-blockers) 
Clozapine and Other medication 
 
FEP: First-episode psychosis; GAF: Global Assessment of Functioning; CGI: Clinical Global Impression 
 
 
 12 
Table 2. Demographical and clinical characteristics of the 142 stable chronic schizophrenia patients treated with 
clozapine. Figure represent mean and (standard deviation) except otherwise specified.  
 
Gender (male / female) 115 / 26 
Age (in years) 44.33 (9.67) 
Age of onset (in years) 22.83 (6.85) 
Tobacco use (%) 47.9% 
Tobacco use (cigarettes/day) 18.07 (8.92) 
Alcohol use (%) 41.1% 
Alcohol units per week    11.14 (11.54) 
Dose of clozapine (mg) 331.03 (141.01) 
Clozapine Monotherapy (%) 39.0% 
Well-being score     
21.64 (3.89) 
GAF score      68.82 (15.09) 
CGI- Positive 
CGI- Negative 
CGI- Depressive 
CGI- Cognitive 
CGI- Overall 
2.68 (1.58) 
3.26 (1.47) 
1.72 (0.99) 
2.94 (1.19) 
3.42 (1.34) 
 
SD: standard deviation; FEP: First-episody psychosis; GAF: Global Assessment of Functioning; CGI: 
Clinical Global   Impression 
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Table 3.  Multiple regression model, with well-being score (from SWEMWBS) as the dependent variable.                         
Variables B Beta t Sig. 
p value 
95.0% Confidence Interval for B 
Lower Bound Upper Bound 
CGI- Positive -.776 -.317 -3.780 <.000 -1.183 -.370 
Overweight (SE) -.651 -.144 -1.681 .095 -1.417 .115 
Clozapine and antidepressants -1.384 -.164 -1.923 .057 -2.808 .040 
 
P value significant at p<0.05 is highlighted in bold,  
B-value=unstandardised coefficient, β-value=standardized coefficient for each determinant  
The excluded determinants are not described in this table. 
SE: Side Effect due to clozapine; CGI: Clinical Global Impression 
 
 
 
Figure 1. Well-being mean scores in chronic schizophrenia patients. 
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Appendix A. Correlations of well-being with demographic and clinical variables in chronic schizophrenia patients. 
Factors correlated with well-being r p 
Age 
.083 .327 
Age of FEP 
-.050 .554 
Smoking amount 
 
-.133 0.016 
Alcohol units 
 
.111 0.171 
Latest Clozapine levels 
-.056 .601 
GPPAQ .062 .471 
CGI- Positive 
 
-.310 <0.000 
CGI- Negative 
 
-.163 0.060 
CGI- Depressive 
 
-.235 0.007 
CGI- Cognitive 
-.094 .397 
CGI- Overall -.200 .017 
GAF .149 .077 
Hypersalivation (SE) -.147 0.082 
Hours of sleep per day (SE) -.020 .814 
Constipation (SE) -.079 .353 
Obsessive symptoms (SE) -.076 .418 
Hypertension (SE) .079 .409 
Overweight (SE) 
 
-.112 0.189 
Hyper-lipidaemia (SE) .045 .658 
Type 2 diabetes mellitus (SE) .050 .610 
Monotherapy (with Clozapine) 
 
.220 0.009 
Clozapine + other antipsychotics 
-.023 .784 
Clozapine + antidepressants .-196 0.019 
Clozapine + drugs for SES 
 
-.164 0.051 
Clozapine + other medication -.057 .502 
 
   Associations p<0.2 are indicated in bold. 
SE: Side Effect due to clozapine, CGI: Clinical Global Impression, GPPAQ: General   Practitioner 
Physical  Activity Questionnaire, GAF: Global Assessment Functioning 
 
 
